Vitrolife

Third quarter

• Sales of SEK 884 (835) million, an organic growth of 6% in local currencies, excluding the exited NACE and GPDx product lines. Total growth was 4% in local currencies and 6% in SEK.
• Sales* per region were +11% in EMEA, +5% in Americas and +2% in APAC.
• Sales* per product group were +1% in Consumables, +21% in Technologies and +5% in Genetics.
• Gross margin increased to 59.2% (58.9).
• Earnings before depreciation and amortisation (EBITDA) amounted to SEK 279 (253) million, resulting in an EBITDA margin of 31.6% (30.3).
• Net income amounted to SEK 124 (102) million, resulting in earnings per share, before and after dilution, of SEK 0.94 (0.75).
• Operating cash flow amounted to SEK 224 (255) million.
• Repurchase of own shares of SEK 246 million under the SEK 500 million programme.

First nine months

• Sales of SEK 2,548 (2,548) million, a growth of 3% in local currencies and flat in SEK, due to a negative currency impact of -3%. Organic growth* was 4%.
• Sales* per region were +4% in EMEA, +6% in Americas and +3% in APAC.
• Sales* per product group were +4% in Consumables, +11% in Technologies and +1% in Genetics.
• Gross margin increased to 59.8% (58.1).
• Earnings before depreciation and amortisation (EBITDA) increased to SEK 825 (753) million, resulting in an EBITDA margin of 32.4% (29.5).
• Net income was SEK 354 (301) million, resulting in earnings per share, before and after dilution, of SEK 2.64 (2.23).
• Operating cash flow amounted to SEK 536 million (475).

* In local currency and excluding exited business of the NACE and GPDx product lines